PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 8320249

The anastomotic aneurysms.

F Sciannameo·P Ronca·M Caselli·A De Sol·D Alberti
View original source ↗Export metadata ↓

Abstract

The authors describe their experience of anastomotic aneurysm diagnosis and treatment. They are classed into two groups: slowly growing anastomotic aneurysms, which are the most common; and rapidly growing anastomotic aneurysms, which are more infrequent. A follow-up is proposed in order to detect this involvement early, in election. Urgent diagnostic timing is also proposed. Moreover an analysis is made of criteria to follow in their therapy and indications to surgical treatment. In the period from January 1988 to October 1992 we observed 413 patients and 876 anastomosis or arterial sutures in election, discovering 27 anastomotic aneurysms whereas in 6 cases we had patients who were affected with rapidly growing anastomotic aneurysms. These were urgently operated, whereas of the 27 patients with slowly growing anastomotic aneurysms, 22 were operated and in 5 cases we preferred to check them by a close follow-up.

Explore related subjects

Anastomosis, SurgicalAneurysm, FalseAortaCarotid ArteriesEmergenciesFemaleFemoral ArteryFollow-Up StudiesHumansIliac ArteryItalyMalePopliteal ArteryPostoperative ComplicationsJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

F Sciannameo, P Ronca, M Caselli, A De Sol, D Alberti. 1993. The anastomotic aneurysms.. https://pubmed.ncbi.nlm.nih.gov/8320249/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1996

Recombinant mitotoxin basic fibroblast growth factor-saporin reduces venous anastomotic intimal hyperplasia in the arteriovenous graft.

BACKGROUND: The plant cytotoxin saporin (SAP) is a potent ribosome-inactivating protein. When conjugated to basic fibroblast growth factor (FGF2), it selectively kills proliferating cells that have upregulated FGF receptors. In this study, we evaluated the effect of the recombinant chimeric mitotoxin rFGF2-SAP on venous anastomotic intimal hyperplasia, a major cause of failure of arteriovenous (AV) grafts. METHODS AND RESULTS: Recently designed expanded polytet-rafluoroethylene-based local infusion devices were implanted bilaterally as femoral AV conduits in six dogs. The venous anastomoses were the sites of continuous delivery of rFGF2-SAP (2.7 micrograms.kg-1.d-1) to one side and vehicle (4.6 microL.kg-1.d-1) as control to the contralateral side for 14 days. All animals survived, and all grafts were patent. Liver enzyme levels and histological analyses of liver, kidneys, and brain were normal, indicating the absence of systemic toxicity. Morphometric measurements and measurements of cell proliferation by bromodeoxyuridine index analysis were performed at both arterial and venous anastomoses. There were no significant differences between the treated grafts and the control grafts in intimal hyperplasia and intimal cell proliferation at the arterial anastomoses. In contrast, rFGF2-SAP reduced intimal thickness by 32%, intimal area by 40%, and cell proliferation index by 33% at the treated venous anastomoses compared with the control venous anastomoses (P < .05). CONCLUSIONS: These data demonstrate that local infusion of rFGF2-SAP significantly reduces venous anastomotic intimal hyperplasia and cell proliferation without systemic toxicity. This study suggests a new strategy for reducing intimal hyperplasia by the selective killing of proliferating smooth muscle cells with a potent chimeric mitotoxin through a novel local infusion device.

Anastomosis, Surgical↗
PubMed1996

Jejunocolostomy or ileocolostomy for treatment of cecal impaction in horses: nine cases (1985-1995).

OBJECTIVE: To determine whether complete cecal bypass, by jejunocolostomy or ileocolostomy, is an effective treatment for horses with cecal impaction. DESIGN: Retrospective analysis of medical records. ANIMALS: 9 horses with cecal impaction managed by jejunocolostomy (3) or ileocolostomy (6) performed with or without typhlotomy for evacuation of cecal contents. PROCEDURE: Information on age, breed, gender, duration of medical treatment, preoperative abnormalities, surgical procedure, and postoperative complications was retrieved from the medical records. Follow-up data were obtained via telephone interview with owners. RESULTS: 6 males and 3 females between 9 and 24 years old (median, 14 years) were included. Five of 9 horses had signs of mild pain associated with reintroduction of food after surgery. All 7 horses for which follow-up information was available were still alive between 7 and 54 months (median, 1.5 years) after surgery. CLINICAL IMPLICATIONS: Jejunocolostomy or ileocolostomy resulted in apparently permanent resolution of cecal impaction in these horses and acceptable long-term outcomes. Mild signs of abdominal pain associated with the onset of feeding can be expected in the early postoperative period.

Anastomosis, Surgical↗
PubMed1996

Delayed/salvage radiation therapy in patients with elevated prostate specific antigen levels after radical prostatectomy. A long term follow-up.

BACKGROUND: In this article the authors report an analysis and long term results of delayed/salvage radiation therapy administered to asymptomatic patients who had an elevated prostate specific antigen (PSA) level, many months to many years after radical prostatectomy. METHODS: During 1987 to 1990, 40 asymptomatic patients were found to have an elevated PSA level 9 to 96 months after radical prostatectomy. The patients underwent transrectal needle aspiration biopsy of the urethrovesicle junction anastomosis (uvj); 28 patients had a positive biopsy and 12 patients had a negative biopsy. Delayed/salvage radiation therapy was administered to the pelvis (45 Gray [Gy]) and prostate bed (59.5 Gy), including the uvj. RESULTS: Twenty-four of 37 patients (65%) were free of clinical disease. In 10 patients (27%), the radiation therapy resulted in a durable decrease in the elevated PSA level below a detectable level for a minimum 5-year follow-up. Five patients were alive with clinical disease. Eight died of disease. Three patients were lost to follow-up. CONCLUSIONS: This experience shows that delayed/salvage radiation therapy to the pelvis (45 Gy) and prostate bed (59.5 Gy), even many years after radical prostatectomy for pathologic stage pB, pC, and pD1 carcinoma of the prostate, was well tolerated and provided freedom from clinical disease in 24 of 37 patients (65%), and a decrease in elevated PSA level in 10 patients (27%). Delayed/salvage radiation therapy appears to be beneficial for patients who had undergone radical prostatectomy only and then developed rising PSA levels during the follow-up period.

Anastomosis, Surgical↗